Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer

NCT01288339 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Panitumumab + FOLFOX (DP)
DRUG: Panitumumab + FOLFOX (no-DP)

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo

Collaborators

[object Object]
[object Object]